Pfizer India, Max Hospitals sign MoU for fellowship programme – ET HealthWorld

New Delhi: Pfizer India announced that it has signed a Memorandum of Understanding (MoU) with Max Super Specialty Hospitals to give fellowships to young doctors in 17 Max Hospitals to gather real-world evidence on drug efficacy and proven therapies from existing Electronic Patient records. This evidence generation will focus on prevention, treatment and management of diseases that are of public health priority in India, such as cancer and cardiovascular disease. The bespoke fellowships will be a form of recognition and will enable young clinicians who want to pursue medical research to do so with clear goals in place.

The fellowship programme will provide young clinicians and researchers at all 17 Max Speciality Hospitals across four states in India, an opportunity to acquire funding and sponsorships for their research work. The selection criteria for these fellowships, will be decided by the medical and research experts at Max Healthcare. Pfizer will provide technical and financial support to the programme.

Pfizer sees this as a long-term, academic collaboration to promote high-quality medical research in the country. Additionally, through this collaboration, Pfizer and Max Hospitals plan to build centres of excellence in rare diseases. The Max hospital will be COE for placing various RWE studies, capability building workshops, fellowship programmes in rare disease areas to start with. This may get extended to other Tas going forward.

Dr Sandeep Budhiraja, group medical director, Max Healthcare, said “Real-world evidence is becoming increasingly important in healthcare decision making. It has the potential to provide invaluable insights and work in synergy with other emerging developments such as a greater use of data science and genomics. Together these efforts can transform the way we look at modern medicine. It gives us immense pleasure to collaborate with Pfizer India, which has taken significant strides into several areas of cutting-edge research, with the aim to solve critical scientific problems.”